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Mycobacterium tuberculosis strains that are resistant
to an increasing number of second-line drugs used to treat
multidrug-resistant tuberculosis (MDR TB) are becoming a
threat to public health worldwide. We surveyed the Network
of Supranational Reference Laboratories for M. tuberculo-
sis isolates that were resistant to second-line anti-TB drugs
during 2000–2004. We defined extensively drug-resistant
TB (XDR TB) as MDR TB with further resistance to >3 of
the 6 classes of second-line drugs. Of 23 eligible laborato-
ries, 14 (61%) contributed data on 17,690 isolates, which
reflected drug susceptibility results from 48 countries. Of
3,520 (19.9%) MDR TB isolates, 347 (9.9%) met criteria for
XDR TB. Further investigation of population-based trends
and expanded efforts to prevent drug resistance and effec-
tively treat patients with MDR TB are crucial for protection
of public health and control of TB.
M
ultidrug-resistant tuberculosis (MDR TB) has been
documented in nearly 90 countries and regions
worldwide (1); 424,203 cases of MDR TB were estimated
to have occurred in 2004, which is 4.3% of all new and
previously treated TB cases (2). Treatment for MDR TB
patients requires use of second-line drugs for >24 months.
These drugs are more costly, toxic, and less effective than
first-line drugs used for routine treatment of TB (3–6). As
with other diseases, resistance to TB drugs results primari-
ly from nonadherence by patients, incorrect drug prescrib-
ing by providers, poor quality drugs, or erratic supply of
drugs (7).
To facilitate treatment of MDR TB in resource-limit-
ed countries, where most TB cases occur (1,2), the World
Health Organization (WHO) and its partners developed the
Green Light Committee, which helps ensure proper use of
second-line drugs, to prevent further drug resistance (8).
Nonetheless, the Green Light Committee encountered
numerous anecdotal reports of MDR TB cases with resist-
ance to most second-line drugs. Once a strain has devel-
oped resistance to second-line drugs, these new TB strains
are even more difficult to treat with existing drugs.
Untreated or inadequately treated patients are at increased
risk of spreading their disease in the community, which
could lead to outbreaks in vulnerable populations and
widespread emergence of a lethal, costly epidemic of drug-
resistant TB, reminiscent of the MDR TB outbreaks in the
early 1990s (9–13). Therefore, to determine whether these
anecdotal reports were isolated events, early evidence of
an emerging epidemic, or the occurrence of virtually
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Switzerlanduntreatable forms of drug-resistant TB that had not been
described previously in different parts of the world, we
characterized and quantified the frequency of second-
line–drug resistance in several geographic regions.
We sought to determine the extent to which highly
resistant  Mycobacterium tuberculosis strains have been
identified by the international laboratories that participate
in the Network of Supranational Reference Laboratories
(SRLs). The SRL Network consists of 25 highly proficient
TB laboratories on 6 continents. These laboratories collab-
orate with national reference laboratories to strengthen
culture and drug-susceptibility testing capacity and to pro-
vide quality control for the WHO/International Union
Against Tuberculosis and Lung Diseases Global Project on
Anti-TB Drug Resistance (14).
Methods
Participants
From November 2004 through November 2005, we
surveyed the global SRL Network. All SRL directors were
invited to participate during the 2004 annual SRLdirectors
meeting, by individual mailings, and by personal phone
calls. Drug-susceptibility testing results were requested for
M. tuberculosis isolates that had been tested for resistance
to first-line drugs and second-line drugs during
2000–2004. Two SRLs were not eligible because they did
not test for second-line drugs or tested for <3 classes of
second-line drugs. 
The 14 SRLs that provided data for this study support
112 TB laboratories in 80 countries worldwide (Figure 1).
SRLs serve as international reference laboratories to a
wide geographic area, performing drug-susceptibility test-
ing that may not be available in a country (e.g., for second-
line drugs) and providing quality assurance for
first-line–drug testing. Most SRLs also serve as the nation-
al reference laboratory for the country in which they are
located; they receive varying proportions of isolates from
their own and other countries for surveillance, clinical
diagnosis, and quality assurance. First-line–drug suscepti-
bility testing is performed on all isolates; second-line–drug
susceptibility testing is usually limited to isolates from
patients known or suspected to have drug-resistant TB. Of
the 14 participating SRLs, not all tested for all 6 classes of
second-line drugs, and 4 did not submit data for the entire
survey period.
In contrast, the SRL in the Republic of Korea serves
as the national reference laboratory and routinely performs
an extended diagnostic panel of drug-susceptibility testing
on isolates from culture-positive TB patients referred from
health centers, hospitals, and clinics in the Republic of
Korea. This SRL tests all isolates for 6 classes of second-
line drugs; thus, data from the Republic of Korea reflect
most culture-positive cases and provide a close approxi-
mation to a population estimate of prevalence. Because of
the large number of isolates received and because sam-
pling for these isolates is systematically different from that
at the other SRLs (testing of all TB patients in the Republic
of Korea vs testing of patients more likely to have drug-
resistant TB in other SRLs), resistance patterns for the
Republic of Korea were analyzed separately from those for
the other SRLs.
Laboratory Methods
Among participating SRLs, different but internation-
ally accepted methods were used to test for second-line
drug resistance (details available upon request). Validation
of drug-susceptibility testing results for second-line drugs
was not performed as part of this survey, but as part of their
role as global reference laboratories, all SRLs participate
in international proficiency testing for first-line drugs.
Quality assurance procedures for second-line–drug sus-
ceptibility testing have not been developed; as a proxy for
quality assurance, we examined the accuracy of second-
line–drug susceptibility testing among isolates susceptible
to the 4 main first-line drugs (isoniazid [INH], rifampin
[RIF], ethambutol, and streptomycin). On the basis of
known mechanisms of drug resistance, finding an isolate
that is susceptible to all first-line drugs and resistant to sec-
ond-line drugs is unlikely (7).
Procedures and Definitions
A standardized reporting form requested anonymous
data for all isolates tested for resistance to >3 second-line
drug classes during 2000–2004. Data were abstracted from
the records, electronic or paper, depending on laboratory
practices for data management. Results were submitted for
1 isolate per patient. Because SRLs rarely receive multiple
isolates from the same patient, reporting of the same
patient more than once was unlikely (B. Metchock and
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Figure 1. Shading indicates 48 countries that submitted at least 1
isolate to participating Supranational Reference Laboratories,
2000–2004. See Table 4 for complete list of participating countries.G.H. Bai, pers. comm.). No specimens were collected for
this study; we used only data from records of isolates that
had already been tested. Limited clinical information about
the patient was available with each isolate. Consistent data
were available for country of origin and date of drug-sus-
ceptibility testing. Data about age and TB treatment histo-
ry were available for <10% of patients, so analysis was not
considered reliable for these variables.
To best compare data for the study samples with data
from the Global Drug Resistance Survey and other popu-
lation-based drug-resistance surveillance, we analyzed
first-line–drug resistance patterns according to standard
methods used in anti-TB–drug resistance surveys (1).
These patterns included any drug resistance, monoresis-
tance (resistance to only the 1 specified drug), polyresis-
tance (resistance to >2 first-line drugs, but which drugs not
specified), and multidrug resistance (resistance to at least
INH and RIF, with or without other drugs). 
We defined 6 classes of second-line drugs as follows:
aminoglycosides other than streptomycin (e.g., kanamycin
and amikacin), cyclic polypeptides (e.g., capreomycin),
fluoroquinolones (e.g., ofloxacin, ciprofloxacin, lev-
ofloxacin, and moxifloxacin), thioamides (e.g., prothion-
amide and ethionamide), serine analogs (e.g., cycloserine
and terizidone), and salicylic acid derivatives (e.g., para-
aminosalicyclic acid).
For this survey we created a consensus definition that
incorporates second-line–drug susceptibility results and is
based on international guidelines for management of drug-
resistant TB (15). The mainstay of an MDR TB treatment
regimen consists of 1 injectible drug (e.g., aminoglycoside
or cyclic polypeptide) and a fluoroquinolone; additional
drugs from the remaining classes are added until the total
reaches 4–6 drugs to which the organism is susceptible. If
the infecting organism is resistant to >3 second-line drug
classes, designing a treatment regimen with sufficient
drugs that are known to be effective against TB is difficult.
Thus, we defined extensively drug-resistant TB (XDR TB)
isolates as those meeting the criteria established for MDR
TB plus resistance to >3 of the 6 classes of second-line
drugs.
Second-line–drug resistance patterns were analyzed
by geographic region from which the isolate was submit-
ted to the SRL. Regions were grouped into epidemiologi-
cally meaningful categories on the basis of prevalence of
TB and MDR TB (1,16). This retrospective survey was
evaluated and approved as public health surveillance by
the US Centers for Disease Control and Prevention (CDC).
Results
We received data for 18,462 patients from 14 (61%) of
23 eligible SRLs. We excluded those patients tested before
2000 (n = 223), tested after 2004 (n = 14), or tested for
resistance to <3 classes of second-line drugs (n = 535). Our
final study sample consisted of 17,690 patients whose iso-
lates were tested for resistance to >3 second-line drugs
during 2000–2004 (Figure 2). Of these, 11,939 (67.5%)
patients were from the Republic of Korea and 5,751
(32.5%) were from the remaining SRLs.
First-line–Drug Susceptibility 
Among isolates from patients from the 13 SRLs other
than the Republic of Korea, 3,765 (65.5%) were resistant
to >1 first-line TB drug (Table 1). Of these, 3,305 (58.5%)
were resistant to at least INH and 2,345 (41.5%) were
resistant to at least RIF. Among isolates from the Republic
of Korea patients, 2,508 (21%) had resistance to any drug;
most (n = 2,196; 18.4%) were resistant to INH.
Single-drug resistance was found for isolates from
884 (15.4%) patients from the 13 SRLs; 456 (8.1%) of
these were resistant to INH and 99 (1.8%) to RIF. Among
isolates from patients from the Republic of Korea, 952
(8%) displayed single-drug resistance, 666 (5.6%) to INH
and 148 (1.2%) to RIF.
Polyresistance other than MDR TB was seen for iso-
lates from 651 (11.5%) patients from the 13 SRLs and 258
(2.2%) from the Republic of Korea SRL. Not all SRLs rou-
tinely tested for resistance to pyrazinamide.
Multidrug resistance (i.e., MDR TB) was present in
isolates from 2,222 (39.4%) patients from the 13 SRLs and
1,298 (10.9%) from the Republic of Korea. Resistance to
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Figure 2. Selection of study sample and summary of drug-resist-
ance patterns of isolates. SRL, Supranational Reference
Laboratory. *Tested before 2000 or after 2004 (n = 247) or tested
for resistance to <3 classes of second-line drugs (n = 535). †Data
for ethambutol resistance missing for 5 isolates. all first-line drugs tested (i.e., MDR TB with additional
resistance to ethambutol and streptomycin) was found in
isolates from 1,017 (18.6%) patients from the 13 SRLs and
233 (2%) from the Republic of Korea SRL.
Second-line–Drug Susceptibility 
Among patients from the 13 SRLs, resistance to
aminoglycosides was detected in 489 (8.7%) isolates and
to fluoroquinolones in 298 (5.3%) (Table 2). Among iso-
lates from Republic of Korea patients, resistance was most
commonly seen to fluoroquinolones (n = 524, 4.4%) and
thioamides (n = 259, 2.2%).
From all SRLs, isolates that were resistant to at least
INH and RIF (i.e., MDR TB; n = 3,520) and tested for sus-
ceptibility to ≥3 second-line drugs were combined for
analysis of second-line–drug resistance patterns.
Resistance to ≥1 class of second-line drug was present in
1,542 (43.8%) MDR TB patients (Table 3). The most com-
monly observed patterns were resistance to aminoglyco-
sides (n = 630, 18.3%), fluoroquinolones (n = 673, 19.3%),
and thioamides (n = 605, 19.3%). 
MDR TB patients whose isolates had further resist-
ance to ≥3 classes of second-line drugs were classified as
XDR TB (Table 3). A total of 347 (9.9%) MDR TB
patients met criteria for XDRTB.  According to the revised
Global XDR TB Task Force definition (www.who.int/
mediacentre/news/notes/2006/np29/en/index.html), 234
(6.6%) isolates met criteria for XDR TB. Among XDR TB
patients, combination drug-resistance patterns included 90
(3.4%) with resistance to aminoglycosides, capreomycin
Extensively Drug-resistant Tuberculosis
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aminoglycosides, fluoroquinolones, and thioamides; and
94 (3.8%) with resistance to fluoroquinolones, thioamides,
and para-aminosalicyclic acid. Nearly half (n = 167,
48.1%) of all XDR TB isolates were resistant to all 4 first-
line drugs, bringing the total to >7 drugs to which the iso-
late was resistant.
The proportion of XDR TB patients by region is
shown in Table 4. Among the group of industrialized
nations, 53 (6.5%) MDR TB patients met criteria for XDR
TB. Among patients from Russia and Eastern Europe, 55
(13.6%) MDR TB patients met criteria for XDR TB.
Among patients from the Republic of Korea, 200 (15.4%)
MDR TB patients, who accounted for 1.7% of all M. tuber-
culosis isolates tested, met criteria for XDR TB.
In evaluating the accuracy of second-line–drug sus-
ceptibility testing, we found that 7 (0.1%) of 11,426
patients fully susceptible to all first-line drugs were resist-
ant to 2 second-line drugs, and 109 (1%) were resistant to
1 second-line drug. Most of these patients were resistant to
fluoroquinolones.
Discussion 
This study represents the first assessment of the wide-
spread occurrence of M. tuberculosis with such extensive
drug resistance as to be nearly untreatable with currently
available drugs, according to international guidelines. We
provide data on second-line–drug resistance for the largest
sample of patients to date, including >5,000 patients from
47 countries, apart from the Republic of Korea. The defini-
tion of XDR TB in this survey is based on WHO guidelines
for the programmatic management of drug-resistant TB; the
guidelines recommend treatment with >4 drugs known to
be effective (15). Therefore, with <3 remaining classes of
second-line drugs to which the infecting organism is sus-
ceptible, treatment of these patients cannot meet interna-
tional standards. XDR TB has been detected in all regions
of the world. XDR TB strains in this study also have high
rates of resistance to pyrazinamide and ethambutol, thereby
severely limiting the treatment options available.
Analysis of combination second-line–drug resistance
patterns is critical for clinicians and policymakers who
design treatment regimens for these patients. Although
limited data exist in the literature about second-line–drug
resistance patterns among MDR TB patients, data from
patients undergoing retreatment for TB in Hong Kong
showed that 30 (17%) MDR TB isolates were resistant to
>3 second-line drugs (17), thereby meeting criteria for
XDR TB. A drug-resistance survey of 447 culture-positive
new patients and patients undergoing retreatment in
Abkhazia, Republic of Georgia, found that of 63 MDR TB
patients, 2 (3%) had additional resistance to 3 second-line
drug classes, consistent with XDR TB (18). More recently,
clusters of XDR TB have been reported in South Africa
and Iran (19,20) and have been associated with HIV infec-
tion and rapid and high death rates.
The emergence of new strains of TB that are resistant
to second-line drugs, especially in settings where TB con-
trol programs have become unable to adequately monitor
treatment regimens for MDR TB, is cause for concern.
After the resurgence of TB in industrialized countries dur-
ing the 1980s and increased awareness of this global prob-
lem, implementation of strong TB control programs based
on the principles of the global directly observed treatment
strategy, short course (DOTS) improved treatment out-
comes and reduced TB and MDR TB incidence in several
countries. This framework for DOTS, promulgated by
WHO, and the pilot MDR TB management projects
(DOTS-Plus projects) became the basis for programmatic
management of MDR TB, which has demonstrated feasi-
bility and effectiveness in low- and middle-income coun-
tries (5,15). However, second-line drugs are available
worldwide outside of well-organized TB-control programs
(WHO, unpub. data).
Improper treatment of drug-resistant TB, such as
using too few drugs, relying on poor quality second-line
drugs, and failing to ensure adherence to treatment, will
likely lead to increases in XDR TB. Strengthening basic
TB programs and infection control measures is crucial for
preventing the selective pressure and environments in
which resistant strains are transmitted from person to per-
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assured and internationally recommended treatment regi-
mens according to WHO guidelines must be scaled up and
strengthened to stem further second-line–drug resistance
and spread of XDR TB. The Green Light Committee pro-
vides a global mechanism to help affected countries
achieve these steps. A commentary published in 2000 pre-
dicted that “failure to institute [the] entire DOTS-Plus
package is likely to destroy the last tools available to com-
bat [TB], and may ultimately result in the victory of the
tubercle bacillus over mankind” (21). XDR TB is an indi-
rect indicator of program failure to adequately diagnose,
prevent, and treat MDR TB.
Documenting the emergence of XDR TB requires a
laboratory-based diagnosis that relies on first- and sec-
ond-line–drug susceptibility testing. A limitation to accu-
rate detection of XDR TB is that existing tests for
resistance to second-line drugs are not yet standardized
and are less reproducible than tests for resistance to INH
and RIF. Lack of international recommendations for use,
as well as lack of standardization and the historical
unavailability of MDR TB treatment in the public sector,
has limited use of second-line–drug susceptibility testing
on a wider scale. As access to treatment with second-line
drugs increases, standardized methods, improved diag-
nostics, and quality assurance for second-line–drug sus-
ceptibility testing are urgently needed to enable reliable
testing and design of appropriate treatment regimens.
Although internationally accepted methods were used by
all laboratories, the precise methods and drug concentra-
tions used varied among participating SRLs (22). Because
these SRLs represent some of the most highly performing
laboratories on 6 continents, results of drug-susceptibility
testing are credible within the context of stated limita-
tions. Initial studies that standardized different methods
for second-line–drug susceptibility testing have been
completed (23–26), but more are needed.
Our study has other limitations. The numbers reported
for XDR TB probably represent an underestimate of the
true number of cases because not all SRLs and not all
national reference laboratories test for all 6 classes of sec-
ond-line drugs. In the absence of test results for all 6 class-
es of second-line drugs, we speculate, on the basis of a
patient’s TB treatment history and known patterns of drug
cross-resistance, that many other unidentified patients are
likely to have had and died from XDR TB. For example, an
MDR TB isolate that is also resistant to an aminoglycoside
and a fluoroquinolone but that has not been tested for the
other second-line drug classes is very likely to be resistant
to an additional second-line drug class for the following
reasons: INH and ethionamide have a 15%–20% rate of
cross-resistance (27); kanamycin and capreomycin cross-
resistance is common, ranging from 20%–60% (CDC,
unpub. data) (28,29); and in this study, isolates that were
resistant to all 4 first-line drugs as well as an aminoglyco-
side and a fluoroquinolone were 70%–80% likely to be
resistant to at least 1 additional class of second-line drug.
Another limitation is that data from most SRLs were
drawn from a convenience sample of isolates and reflect
referral bias. Thus, these data can not be considered repre-
sentative of a patient population or region, and actual
denominators are difficult to determine. For this reason,
although estimates of prevalence are possible, they cannot
be generalized to the local or regional population.
However, our study is the first to report XDR TB patients
in multiple geographic regions; future systematic surveys
are needed to determine the true extent of this disease.
Data from the Republic of Korea reflect a more compre-
hensive policy for drug-susceptibility testing and provide
an estimate of the population prevalence in this setting.
Extensively Drug-resistant Tuberculosis
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Korea is higher than rates reported from other national
drug resistance surveys and may reflect other unknown
referral biases (1).
Lastly, we had limited clinical information about each
patient because information submitted to each SRL varied
and was not reliably available for inclusion in the analysis.
Data about TB treatment history, patient age and sex, or
HIV status are not routinely collected by all laboratories.
Genotyping data were not available to confirm whether
XDR TB isolates are related to W variant of the Beijing
strain, a highly drug-resistant strain of M. tuberculosis
responsible for large nosocomial outbreaks in New York in
the early 1990s (30).
Despite these limitations, our survey provides the first
documentation of the emergence of XDR TB as a serious
worldwide public health threat. XDR TB was identified on
6 continents and is significantly associated with worse
treatment outcomes than MDR TB (31,32). The emergence
of XDR TB, coupled with the increased use of second-line
drugs, suggests that urgent measures are needed to
improve rational use of quality-assured second-line drugs.
In addition, population-based surveillance for second-
line–drug susceptibility testing is needed to better describe
the magnitude of XDR TB worldwide, track trends, and
plan a public health response. Indeed, the convergence of
XDR TB with the HIV epidemic may undermine gains in
HIV prevention and treatment programs and requires
urgent interventions. These interventions include ensuring
adherence to recommended international standards of care
aimed at promptly and reliably diagnosing TB, ensuring
adherence to recommended treatment regimens with
demonstrated efficacy, implementing infection control pre-
cautions where patients congregate, and improving labora-
tories’ capacity to accurately and rapidly detect
drug-resistant M. tuberculosis isolates so that patients can
receive effective treatment (33). Other unmet needs
include further development of international standards for
second-line–drug susceptibility testing, new anti-TB drug
regimens, and better diagnostic tests for TB and MDR TB.
Such measures are crucial if future generations are to be
protected from potentially untreatable TB.
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